Podcasts
>
>
Radiopharmaceuticals for Breast Cancer

Radiopharmaceuticals for Breast Cancer

Early studies are ongoing for metastatic HER2-negative and triple-negative breast cancer.
Radiopharmaceuticals 2466x1644

Nuclear medicine physician Dr. Munir Ghesani is studying how radiopharmaceuticals — drugs that contain a small amount of radioactive material — can be used to treat metastatic HER2-negative and triple-negative breast cancer. While the studies are very early, he’s very hopeful about the results.

Listen to the episode to hear Dr. Ghesani explain:

  • how radiopharmaceuticals work

  • the side effects radiopharmaceuticals can cause

  • how doctors decide which radioactive substance is best for treating specific cancers

00:00
 
About the guests
 
Munir Ghesani headshot
Munir Ghesani, MD, FACNM, FACR, FACNM

Munir Ghesani, MD, FACNM, FACR, FACNM, is a nuclear medicine physician and chief medical officer at United Theranostics in Minneapolis, MN, and medical director at United Theranostics in Princeton, NJ.

Was this article helpful?
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate